DCGI extends shelf life of Covishield vaccine from six to nine months

India's drug regulator DCGI has extended the shelf life of Covishield, the Oxford-AstraZeneca COVID-19 vaccine, from six to nine months from its manufacturing date.

Covishield
(Photo: Reuters)
Press Trust of India New Delhi
1 min read Last Updated : Mar 31 2021 | 10:24 PM IST

India's drug regulator DCGI has extended the shelf life of Covishield, the Oxford-AstraZeneca COVID-19 vaccine, from six to nine months from its manufacturing date.

In a letter to the Serum Institute of India (SII), Drugs Controller General of India V G Somani said the SII is permitted to apply the vaccine's shelf life of nine months to unlabelled vials available on hand.

Shelf life is the length of time for which an item remains fit for use.

The Drugs Controller General of India (DCGI) said it has no objection in respect of 'Extension of Shelf Life of Covishield Vaccine' in multi-dose glass vial (10 dose-5ml) from six months to nine months.

"You are permitted to apply the shelf life of nine months to unlabelled vials available on hand, subject to the condition that the details of such stock, batch-wise, shall be submitted to this office and Central Drugs Laboratory, Kasauli," Somani said in the letter.

According to an update by UK drug regulator dated February 22, the shelf-life of the AstraZeneca COVID-19 vaccine is six months.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineHealth MinistryDrug Controller General of India

First Published: Mar 31 2021 | 10:06 PM IST

Next Story